Mereo BioPharma Income Before Tax Over Time
| MREO Stock | USD 3.35 0.06 1.82% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Mereo BioPharma Performance and Mereo BioPharma Correlation. Mereo |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Mereo BioPharma. If investors know Mereo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Mereo BioPharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.25) | Revenue Per Share 0.007 | Return On Assets (0.24) | Return On Equity (0.48) |
The market value of Mereo BioPharma Group is measured differently than its book value, which is the value of Mereo that is recorded on the company's balance sheet. Investors also form their own opinion of Mereo BioPharma's value that differs from its market value or its book value, called intrinsic value, which is Mereo BioPharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Mereo BioPharma's market value can be influenced by many factors that don't directly affect Mereo BioPharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Mereo BioPharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Mereo BioPharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Mereo BioPharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Income Before Tax Analysis
Compare Mereo BioPharma Group and related stocks such as Terns Pharmaceuticals, PDS Biotechnology Corp, and Inozyme Pharma Income Before Tax Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| TERN | (18.1 M) | (18.1 M) | (18.1 M) | (18.1 M) | (18.1 M) | (18.1 M) | (18.1 M) | (18.1 M) | (18.1 M) | (68.8 M) | (39.8 M) | (49.6 M) | (60 M) | (90 M) | (85.5 M) |
| PDSB | (7.3 M) | (7.3 M) | (7.3 M) | (7.3 M) | (12.8 M) | (29.2 M) | (40.7 M) | (53.4 M) | (43.6 M) | (7.4 M) | (14.8 M) | (21.4 M) | (42.1 M) | (44.3 M) | (46.6 M) |
| INZY | (7 M) | (7 M) | (7 M) | (7 M) | (7 M) | (7 M) | (7 M) | (7 M) | (7 M) | (19.7 M) | (56.4 M) | (56.6 M) | (67.1 M) | (71.2 M) | (74.7 M) |
| HOOK | (12.7 M) | (12.7 M) | (12.7 M) | (12.7 M) | (12.7 M) | (12.7 M) | (12.7 M) | (12.7 M) | (16.2 M) | (43 M) | (44.1 M) | (75.7 M) | (64.9 M) | (81.2 M) | (77.2 M) |
| DAWN | (17 M) | (17 M) | (17 M) | (17 M) | (17 M) | (17 M) | (17 M) | (17 M) | (17 M) | (17 M) | (43.8 M) | (72.8 M) | (142.2 M) | (188.9 M) | (179.5 M) |
| XFOR | (13.2 M) | (13.2 M) | (13.2 M) | (13.2 M) | (13.2 M) | (13.2 M) | (23 M) | (33.9 M) | (43 M) | (52.8 M) | (62 M) | (88.7 M) | (93.8 M) | (101.1 M) | (96 M) |
| ABOS | (7.9 M) | (7.9 M) | (7.9 M) | (7.9 M) | (7.9 M) | (7.9 M) | (7.9 M) | (7.9 M) | (7.9 M) | (7.9 M) | (7.3 M) | (100.6 M) | (42.9 M) | (52.4 M) | (55 M) |
| ELEV | (5.9 M) | (5.9 M) | (5.9 M) | (5.9 M) | (5.9 M) | (5.9 M) | (5.9 M) | (5.9 M) | (5.9 M) | (5.9 M) | (17.3 M) | (32 M) | (95.1 M) | (45.7 M) | (48 M) |
| HEPA | (843 K) | (843 K) | (843 K) | (5.3 M) | (5.3 M) | (14.3 M) | (17 M) | (16.8 M) | (10 M) | (7.9 M) | (20.3 M) | (32.7 M) | (45.1 M) | (49.3 M) | (46.9 M) |
Mereo BioPharma Group and related stocks such as Terns Pharmaceuticals, PDS Biotechnology Corp, and Inozyme Pharma Income Before Tax description
Income Before Tax which can also be referred as pre-tax income is reported on Mereo BioPharma income statement and is an important metric when analyzing Mereo BioPharma Group profitability. Accounting techniques because taxes can be complex, and not perfectly consistent from one company to company, an analyst may use pre-tax income as a more stable measure of profitability.My Equities
My Current Equities and Potential Positions
| Mereo BioPharma Group | MREO |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Location | United Kingdom |
| Exchange | NASDAQ Exchange |
USD 3.35
Check out Mereo BioPharma Performance and Mereo BioPharma Correlation. You can also try the CEOs Directory module to screen CEOs from public companies around the world.
Mereo BioPharma technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.